Severe hypoglycemia with trastuzumab: An unseen adverse event

CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 149
DOI: 10.4103/sajc.sajc_400_18

Letter to the Editor

Authors

B. P. Amrith

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Parveen Jain

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Krushna A. Chaudhari

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Mansi Sharma

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Ullas Batra

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

References
1 Hudis CA. Trastuzumab – Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
2 FDA Label-Trastuzumab. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf. [Last accessed on 2018 Nov 15].
3 Herceptin and Hypoglycemia – From FDA Reports, eHealthME; November, 2018. Available from: https://www.ehealthme.com/ds/herceptin/hypoglycemia. [Last accessed on 2018 Nov 15].